Retrospective comparison of flot and modified dcf as first-line chemotherapy in metastatic gastric adenocarcinoma

Creative Commons License

Gurler F., GÜVEN D. C., Aydemir E., SÜTCÜOĞLU O., Inci B. K., ARIK Z., ...Daha Fazla

TURKISH JOURNAL OF MEDICAL SCIENCES, cilt.52, sa.5, ss.1559-1568, 2022 (SCI-Expanded) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 52 Sayı: 5
  • Basım Tarihi: 2022
  • Doi Numarası: 10.55730/1300-0144.5496
  • Dergi Adı: TURKISH JOURNAL OF MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.1559-1568
  • Anahtar Kelimeler: FLOT, gastric cancer, gastroeosephageal cancer, modified DCF, PHASE-II, SYSTEMIC CHEMOTHERAPY, MODIFIED DOCETAXEL, PLUS CHEMOTHERAPY, FLUOROURACIL DCF, JUNCTION CANCER, CISPLATIN, 5-FLUOROURACIL, OXALIPLATIN, LEUCOVORIN
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Background/aim: The aim of our study was to compare the efficacy and the safety of the FLOT and the modified DCF (mDCF) regimens in patients with metastatic gastric (GC) and gastroesophageal junction (GEJ) adenocarcinoma as first-line treatment.